Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib. | Cancer Cell Int;21(1): 198, 2021 Apr 08. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib.

Yang, Jingmei; Lindström, H Jonathan G; Friedman, Ran.

Affiliation

Yang J; Department of Chemistry and Biomedical Science, Linnaeus University, Kalmar Campus, Kalmar, 391 82, Sweden.
Lindström HJG; Department of Chemistry and Biomedical Science, Linnaeus University, Kalmar Campus, Kalmar, 391 82, Sweden.
Friedman R; Faeth Therapeutics Inc., 237 Kearny Street, #9245, San Francisco, CA, 94108, US.

Cancer Cell Int ; 21(1): 198, 2021 Apr 08.

Article in En | MEDLINE | ID: mdl-33832508

Key words

Acute myeloid leukaemia; FLT3; kinase inhibitors

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Language: En Journal: Cancer Cell Int Year: 2021 Document type: Article Affiliation country:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Language: En Journal: Cancer Cell Int Year: 2021 Document type: Article Affiliation country: